New combo therapy shows promise for Hard-to-Treat breast cancer on chest wall
Disease control
Completed
This study tested whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug carboplatin works better than carboplatin alone for breast cancer that has returned on the chest wall. The trial included 76 people with either triple-negative or hormone-resistant brea…
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC